Boston Scientific Caps Strong 2025 with Double-Digit Growth, Eyes Further Expansion Through Strategic Acquisitions
Boston Scientific (NYSE: BSX) reported robust fourth-quarter and full-year 2025 results, exceeding guidance on key metrics. The medical device leader issued confident 2026 forecasts, underpinned by broad-based performance, margin expansion, and an active pipeline of tuck-in acquisitions like the pending Penumbra deal.